Palisade Bio, Inc. (PALI)
NASDAQ: PALI · Real-Time Price · USD
1.710
+0.080 (4.91%)
Mar 9, 2026, 3:50 PM EDT - Market open
Palisade Bio Market Cap
Palisade Bio has a market cap or net worth of $254.80 million as of March 9, 2026. Its market cap has increased by 9,299.76% in one year.
Market Cap
254.80M
Enterprise Value
248.29M
1-Year Change
9,299.76%
Ranking
Category
Stock Price
$1.71
Market Cap Chart
Since April 28, 2021, Palisade Bio's market cap has increased from $75.07M to $254.80M, an increase of 239.42%. That is a compound annual growth rate of 28.61%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Mar 6, 2026 | 242.88M | -30.64% |
| Dec 31, 2025 | 350.16M | 7,572.39% |
| Dec 31, 2024 | 4.56M | -16.56% |
| Dec 29, 2023 | 5.47M | -31.77% |
| Dec 30, 2022 | 8.02M | -54.57% |
| Dec 31, 2021 | 17.65M | -76.49% |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Prelude Therapeutics | 267.79M |
| Cellectis | 265.08M |
| Ovid Therapeutics | 264.27M |
| Context Therapeutics | 264.15M |
| Cybin | 262.19M |
| Orchestra BioMed Holdings | 254.09M |
| Inhibikase Therapeutics | 251.68M |
| Fennec Pharmaceuticals | 250.17M |